Alnilam Pharmaceuticals had a trading volume of $382 million on February 18, ranking 331st among U.S. stocks on that day.

On February 18, 2026, Alnylam Pharmaceuticals (ALNY) had a trading volume of $382 million, ranking 331st among U.S. stocks for the day. The trading volume decreased by 24.09% compared to the previous day, with a daily trading volume of 1.1512 million shares.

Alnylam Pharmaceuticals (ALNY) rose 0.02% on February 18, 2026, closing at $332.68. The stock has increased by 3.23% over the past five trading days, declined by 1.59% for the entire month of February, and has fallen 16.34% since the beginning of the year. Over the past 52 weeks, it has increased by 33.07%.

*If the company’s listing period is less than 52 weeks, the 52-week change is calculated from the listing date to now (this also applies to cases where the listing period is less than one month or fewer than five trading days).

On February 18, 2026, HC Wainwright & Co. reaffirmed an “Buy” rating for Alnylam Pharmaceuticals, with a target price of $510.

Alnylam Pharmaceuticals, Inc. is a Delaware corporation founded in May 2003. The company is a biopharmaceutical firm focused on developing new therapies based on RNA or RNA interference (RNAi). RNAi is a natural process in cells that selectively silences or regulates the expression of specific genes. Since many diseases are caused by abnormal activity of certain genes, RNAi’s ability to selectively silence genes offers a new approach to treating numerous human diseases. The company believes that drugs based on RNAi have the potential to become a new class of pharmaceuticals, alongside small molecules, protein drugs, and antibody drugs. With established RNAi intellectual property and technical expertise, the company is developing biochemical methods to help build a systematic platform for developing improved RNAi therapies for various diseases.